Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or ...

Findings showed both zanidatamab treatment arms demonstrated statistically significant and clinically meaningful improvements in PFS vs the SOC arm.

Congress 2025 took place in Berlin, Germany, a dynamic epicentre known for its blend of innovation, culture, and historical ...

"Kelun-Biotech’s ADC plus Keytruda touts first-line success in late-stage NSCLC" was originally created and published by ...

The study will test the combination, which aims to boost CD19 expression to make CAR T-cell therapy more effective, in patients with solid tumors.

Imfinzi is the first immunotherapy approved for perioperative use to treat gastric and gastroesophageal junction cancers.

Second, for our mRNA cancer immunotherapies, we have recently provided 2 Phase II updates that support and inform our current ...

Different subsets of γδ T cells display differential expression of immune checkpoint receptors (ICRs) and have distinct ...

The Poco F8 Ultra has a 6.9-inch OLED display, which Poco calls HyperRGB - their 'full RGB subpixel structure' does appear to ...

Bristol Myers Squibb today announced the presentation of more than 95 data disclosures, including 27 oral presentations, across company-sponsored studies and external collaborations at the 67th ...

The FDA has granted fast track designation (FTD) to AVZO-103, a potential best-in-class Nectin4/TROP2 bispecific antibody-drug conjugate (ADC) for the treatment of patients with locally advanced or ...

Lung cancer remains the most frequently diagnosed malignancy and the leading cause of cancer tumour-related mortality ...